Japan’s Daiichi Sankyo Company and Maruishi Pharmaceutical Co. Ltd have signed an agreement to collaborate on the commercialization of the general anaesthesia analgesic, generic Remifentanil injection, for which Maruishi Pharmaceutical is 
currently applying for a manufacture and marketing license. Remifentanil injection is widely used as an opioid analgesic (μ-opioid receptor agonist) to manage general anaesthesia. It is an ultra short-acting analgesic used for general anaesthesia characterized by its potent analgesic action together with its superior ability to rapidly regulate pain.
Once Maruishi Pharmaceutical has acquired a license for the manufacturing and marketing of this drug, the plan is for Maruishi Pharmaceutical to handle its manufacture and Daiichi Sankyo to handle its marketing, while both companies will jointly conduct promotion activities.
